# PROSPER RCC (NCT03055013)

> Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03055013
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
- Interventions: Nephrectomy; Nivolumab; Patient Observation; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 819
- Primary outcome: Recurrence-free Survival (RFS) Rate at 5 Years

## Indexed commentary on PROSPER RCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 5
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=prosper-rcc-nct03055013

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03055013", "email": "<work email>"}; the inbox owner confirms by the emailed link.